# Levetiracetam

## Keppra inj 500mg/5mL

##### 臨採

| TAH Drug Code      | IKEP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Focal (partial) onset: Adjunctive therapy in the treatment of focal (partial) onset seizures in adults and children >=4 years of age and >20 kg with epilepsy. Generalized onset: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and 16 years and older with idiopathic generalized epilepsy.                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Monotherapy: Adults, 16 Years and Older: Initial, 250 mg twice daily IV/orally; titration, may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults, 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily, increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Loss of appetite (3% to 8% ), Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% ), Neck pain (2% to 8% ) Neurologic: Asthenia (15% ), Dizziness (5% to 9% ), Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% ), Irritability (6% to 12% ) Respiratory: Cough (2% to 9% ), Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome, Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production, Decreased white blood cell count (2.4% to 3.2% ), Eosinophil count raised (8.6% ), Neutropenia ( 2.4% ), Pancytopenia, Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% ), Suicide Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Keppra solution 100mg/mL， 300mL

##### 臨採

| TAH Drug Code      | LKEP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Focal (partial) onset: Adjunctive therapy in the treatment of focal (partial) onset seizures in adults and children ?4 years of age and >20 kg with epilepsy. Generalized onset: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and 16 years and older with idiopathic generalized epilepsy.                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Monotherapy: Adults, 16 Years and Older: Initial, 250 mg twice daily IV/orally; titration, may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults, 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily, increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Loss of appetite (3% to 8% ), Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% ), Neck pain (2% to 8% ) Neurologic: Asthenia (15% ), Dizziness (5% to 9% ), Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% ), Irritability (6% to 12% ) Respiratory: Cough (2% to 9% ), Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome, Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production, Decreased white blood cell count (2.4% to 3.2% ), Eosinophil count raised (8.6% ), Neutropenia ( 2.4% ), Pancytopenia, Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% ), Suicide Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Keppra 500mg

##### 

| TAH Drug Code      | OKEP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Focal (partial) onset: Adjunctive therapy in the treatment of focal (partial) onset seizures in adults and children ?4 years of age and >20 kg with epilepsy. Generalized onset: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and 16 years and older with idiopathic generalized epilepsy.                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Monotherapy: Adults, 16 Years and Older: Initial, 250 mg twice daily IV/orally; titration, may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum: 3000 mg/day. Adjunctive therapy: Adults, 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily, increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily. Child >6 years and dosage <250mg should use solution of Levetiracetam.                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Loss of appetite (3% to 8% ), Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% ), Neck pain (2% to 8% ) Neurologic: Asthenia (15% ), Dizziness (5% to 9% ), Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% ), Irritability (6% to 12% ) Respiratory: Cough (2% to 9% ), Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome, Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production, Decreased white blood cell count (2.4% to 3.2% ), Eosinophil count raised (8.6% ), Neutropenia ( 2.4% ), Pancytopenia, Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% ), Suicide Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

